Jianguang Ji1, Kari Hemminki. 1. Center for Family Medicine, Karolinska Institute, Alfred Nobels Alle 12, 14183 Huddinge, Sweden. jianguang.ji@ki.se
Abstract
BACKGROUND: Improved survival for breast cancer is increasing the likelihood of contralateral tumors. Mammographic screening is partially contributing to the survival advantage, while changing many aspects of breast cancer presentation, including age at diagnosis, histology and familial risk. As mammography has become widely used, it is important to quantify the risks for contralateral breast cancer in a population with a national access to mammographic screening service. METHODS: The nation-wide Swedish Family-Cancer Database was used to calculate risks for contralateral breast cancer between years 1990 (1993) and 2002. The standardized incidence ratio (SIR) measured the risk for contralateral breast compared to first breast cancer. RESULTS: The risks for contralateral breast cancer ranged between 1.85 and 3.79, and they tended to be higher when in situ cancer was diagnosed. Family history and early diagnosis of first cancer increased the risks for contralateral breast cancer, approximately equally for invasive and in situ cancers. The risk for contralateral in situ cancer was 9.01 following two independent invasive cancers. The risk for the same, concordant histology between the first and the contralateral cancer was higher than that for discordant histologies. The risks for concordant histologies were particularly high for mucinous (12.16), comedo (11.74) and lobular (5.06) tumors. When the first lobular cancer was diagnosed before age 45 years, the risk for contralateral lobular cancer was 32.20. CONCLUSION: In situ breast cancer poses an approximately equally high risk as invasive cancer. Family history and earlier age of onset are associated with high risks needing clinical attention.
BACKGROUND: Improved survival for breast cancer is increasing the likelihood of contralateral tumors. Mammographic screening is partially contributing to the survival advantage, while changing many aspects of breast cancer presentation, including age at diagnosis, histology and familial risk. As mammography has become widely used, it is important to quantify the risks for contralateral breast cancer in a population with a national access to mammographic screening service. METHODS: The nation-wide Swedish Family-Cancer Database was used to calculate risks for contralateral breast cancer between years 1990 (1993) and 2002. The standardized incidence ratio (SIR) measured the risk for contralateral breast compared to first breast cancer. RESULTS: The risks for contralateral breast cancer ranged between 1.85 and 3.79, and they tended to be higher when in situ cancer was diagnosed. Family history and early diagnosis of first cancer increased the risks for contralateral breast cancer, approximately equally for invasive and in situ cancers. The risk for contralateral in situ cancer was 9.01 following two independent invasive cancers. The risk for the same, concordant histology between the first and the contralateral cancer was higher than that for discordant histologies. The risks for concordant histologies were particularly high for mucinous (12.16), comedo (11.74) and lobular (5.06) tumors. When the first lobular cancer was diagnosed before age 45 years, the risk for contralateral lobular cancer was 32.20. CONCLUSION: In situ breast cancer poses an approximately equally high risk as invasive cancer. Family history and earlier age of onset are associated with high risks needing clinical attention.
Authors: Anne S Reiner; Julia Sisti; Esther M John; Charles F Lynch; Jennifer D Brooks; Lene Mellemkjær; John D Boice; Julia A Knight; Patrick Concannon; Marinela Capanu; Marc Tischkowitz; Mark Robson; Xiaolin Liang; Meghan Woods; David V Conti; David Duggan; Roy Shore; Daniel O Stram; Duncan C Thomas; Kathleen E Malone; Leslie Bernstein; Jonine L Bernstein Journal: J Clin Oncol Date: 2018-04-05 Impact factor: 44.544
Authors: Anne S Reiner; Esther M John; Jennifer D Brooks; Charles F Lynch; Leslie Bernstein; Lene Mellemkjær; Kathleen E Malone; Julia A Knight; Marinela Capanu; Sharon N Teraoka; Patrick Concannon; Xiaolin Liang; Jane C Figueiredo; Susan A Smith; Marilyn Stovall; Malcolm C Pike; Robert W Haile; Duncan C Thomas; Colin B Begg; Jonine L Bernstein Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544
Authors: Anne S Reiner; Charles F Lynch; Julia S Sisti; Esther M John; Jennifer D Brooks; Leslie Bernstein; Julia A Knight; Li Hsu; Patrick Concannon; Lene Mellemkjær; Marc Tischkowitz; Robert W Haile; Ronglai Shen; Kathleen E Malone; Meghan Woods; Xiaolin Liang; Monica Morrow; Jonine L Bernstein Journal: Breast Cancer Res Date: 2017-07-19 Impact factor: 6.466
Authors: Helena Sackey; Miao Hui; Kamila Czene; Helena Verkooijen; Gustaf Edgren; Jan Frisell; Mikael Hartman Journal: Breast Cancer Res Date: 2016-10-18 Impact factor: 6.466